Reassure based on current evidence (no excess malformation risk)
Successful drug development calls for robust assessment of the fate of a drug from its introduction to the patient through absorption and metabolism to excretion
Prescribing decisions rest with those independent clinicians, not with the platform
Among 21,822 people of European ancestry, we required participants to have complete data needed to construct the target phenotype and GWAS covariates (that is, data available for pre-treatment weight, post-treatment weight, drug type, dosage, time on treatment and factors such as age, sex and height), resulting in 18,488 participants
Designs for Health wrap the molecule in a liposomal delivery to get it through intact, so a meaningful amount actually reaches your cells rather than ending in the gut, the difference between a headline ingredient and a working dose